Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type Journal Article
PMID (31046839)
Authors Aznar MA, Planelles L, Perez-Olivares M, Molina C, Garasa S, Etxeberría I, Perez G, Rodriguez I, Bolaños E, Lopez-Casas P, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Teijeira A, Quintero M, Melero I
Title Immunotherapeutic effects of intratumoral nanoplexed poly I:C.
Journal Journal for immunotherapy of cancer
Vol 7
Issue 1
Date 2019 05 02
URL
Abstract Text Poly I:C is a powerful immune adjuvant as a result of its agonist activities on TLR-3, MDA5 and RIG-I. BO-112 is a nanoplexed formulation of Poly I:C complexed with polyethylenimine that causes tumor cell apoptosis showing immunogenic cell death features and which upon intratumoral release results in more prominent tumor infiltration by T lymphocytes. Intratumoral treatment with BO-112 of subcutaneous tumors derived from MC38, 4 T1 and B16-F10 leads to remarkable local disease control dependent on type-1 interferon and gamma-interferon. Some degree of control of non-injected tumor lesions following BO-112 intratumoral treatment was found in mice bearing bilateral B16-OVA melanomas, an activity which was enhanced with co-treatment with systemic anti-CD137 and anti-PD-L1 mAbs. More abundant CD8+ T lymphocytes were found in B16-OVA tumor-draining lymph nodes and in the tumor microenvironment following intratumoral BO-112 treatment, with enhanced numbers of tumor antigen-specific cytotoxic T lymphocytes. Genome-wide transcriptome analyses of injected tumor lesions were consistent with a marked upregulation of the type-I interferon pathway. Inspired by these data, intratumorally delivered BO-112 is being tested in cancer patients (NCT02828098).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
BO-112 BO 112|BO112 BO-112 is a nanoparticle formulation of a synthetic double stranded RNA (poly I:C) complex, which potentially enhances anti-tumor immune response, induces apoptosis, and decreases tumor growth (PMID: 31046839).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown melanoma not applicable BO-112 Preclinical - Patient cell culture Actionable In a preclinical study, BO-112 treatment inhibited cell viability and induced apoptosis in mouse melanoma cells, and induced cytotoxicity and increased apoptosis in cells derived from metastatic lesions of melanoma patients in culture, and intratumoral delivery of BO-112 enhanced infiltration of T-lymphocytes, reduced tumor growth, and delayed progression in syngeneic mouse models (PMID: 31046839). 31046839
Unknown unknown breast cancer not applicable BO-112 Preclinical - Cell culture Actionable In a preclinical study, BO-112 treatment induced cytotoxicity in human breast cancer cell lines and inhibited viability of mouse triple-negative breast cancer (TNBC) cells in culture, and intratumoral delivery of BO-112 reduced tumor growth in a syngeneic mouse model of TNBC (PMID: 31046839). 31046839
Unknown unknown colon cancer not applicable BO-112 Preclinical - Cell culture Actionable In a preclinical study, BO-112 treatment inhibited viability of mouse colon carcinoma cells, and reduced cell viability, and induced cytotoxicity and apoptosis in human colon cancer cell lines in culture, and intratumoral delivery of BO-112 reduced tumor growth in a syngeneic mouse model of colon carcinoma (PMID: 31046839). 31046839